Regeneron Pharmaceuticals (REGN) Change in Receivables (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Change in Receivables of $838.5 million for Q2 2026, up 2873.4% year-over-year from $28.2 million in Q2 2025, and up 69975.0% quarter-over-quarter from -$1.2 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Change in Receivables (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at $838.5 million for Q2 2026.
- In Q2 2026, Change in Receivables rose 2873.4% year-over-year to $838.5 million; the TTM figure through Jun 2026 stood at $968.8 million (up 888.28% YoY), while the FY2025 annual figure was -$498.1 million, down 189.91% from the prior year.
- Change in Receivables for Q2 2026 stood at $838.5 million, up from -$1.2 million in the prior quarter.
- The five-year high for Change in Receivables was $838.5 million in Q2 2026, with the low at -$1.2 billion in Q1 2022.
- The 5-year median for Change in Receivables is $65.8 million (2025), against an average of $29.1 million.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables plunged 2154.03% in 2022, then soared 18200.0% in 2024.
- Regeneron Pharmaceuticals' Change in Receivables stood at -$219.6 million in 2022, then surged by 137.66% to $82.7 million in 2023, then soared by 42.44% to $117.8 million in 2024, then plunged by 56.54% to $51.2 million in 2025, then surged by 1537.7% to $838.5 million in 2026.
- Business Quant data shows REGN's Change in Receivables at $838.5 million in Q2 2026, -$1.2 million in Q1 2026, and $51.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 838.50 Mn |
| Jun 30, 2026 | 838.50 Mn |
| Mar 31, 2026 | -1.20 Mn |
| Mar 31, 2026 | -1.20 Mn |
| Dec 31, 2025 | 51.20 Mn |
| Dec 31, 2025 | 51.20 Mn |
| Sep 30, 2025 | 80.30 Mn |
| Sep 30, 2025 | 80.30 Mn |
| Jun 30, 2025 | 28.20 Mn |
| Jun 30, 2025 | 28.20 Mn |
| Mar 31, 2025 | -657.80 Mn |
| Mar 31, 2025 | -657.80 Mn |
| Dec 31, 2024 | 117.80 Mn |
| Dec 31, 2024 | 117.80 Mn |
| Sep 30, 2024 | 388.90 Mn |
| Sep 30, 2024 | 388.90 Mn |
| Jun 30, 2024 | 494.10 Mn |
| Jun 30, 2024 | 494.10 Mn |
| Mar 31, 2024 | -446.80 Mn |
| Mar 31, 2024 | -446.80 Mn |